WO2024114762A1 - 一种多肽抑制剂、其制备方法和应用 - Google Patents

一种多肽抑制剂、其制备方法和应用 Download PDF

Info

Publication number
WO2024114762A1
WO2024114762A1 PCT/CN2023/135637 CN2023135637W WO2024114762A1 WO 2024114762 A1 WO2024114762 A1 WO 2024114762A1 CN 2023135637 W CN2023135637 W CN 2023135637W WO 2024114762 A1 WO2024114762 A1 WO 2024114762A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acids
alkyl
integer
compound
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/135637
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
董加强
俞文胜
陈运
程宝
龚珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority to KR1020257019116A priority Critical patent/KR20250111134A/ko
Priority to CN202380079192.7A priority patent/CN120202212A/zh
Priority to US19/133,875 priority patent/US20260193294A1/en
Priority to JP2025531331A priority patent/JP2025540765A/ja
Priority to EP23896904.2A priority patent/EP4628499A1/en
Priority to AU2023404553A priority patent/AU2023404553A1/en
Priority to IL321139A priority patent/IL321139A/en
Publication of WO2024114762A1 publication Critical patent/WO2024114762A1/zh
Priority to MX2025006152A priority patent/MX2025006152A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention belongs to the field of biomedicine, and specifically relates to a polypeptide inhibitor and a preparation method and application thereof.
  • the cytokine IL23 plays an important role in the body's natural and adaptive immunity. IL-23 induces lymphocytes to express inflammatory cytokines, the most notable of which are helper T cells (TH17), innate lymphoid cells (ILCs), and ⁇ T cells.
  • the IL-23 heterodimeric receptor is composed of two subunits, IL-23R and IL-12R ⁇ 1, with IL-23R being a subunit unique to the IL-23 pathway. IL-12R ⁇ 1 is shared with the IL-12 receptor.
  • the IL-23 cytokine is composed of two subunits, p19 and p40, with the p19 subunit being unique to IL-23 and p40 being shared with IL-12.
  • Th17 cells provide the necessary conditions for the generation and survival of Th17 cells.
  • Th17 cells play a vital role in the pathology of many autoimmune diseases, including inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus (SLE) and multiple sclerosis (MS).
  • SLE systemic lupus erythematosus
  • MS multiple sclerosis
  • antibody therapy includes high production costs, poorer stability, higher requirements for transportation, storage, use and production conditions, and usually require infusion or injection during treatment, which is a challenge for patient compliance.
  • Antibody immunosuppressive therapy is usually systemic, and tuberculosis patients receiving treatment are at risk of relapse and other serious infections. Therefore, a high proportion of patients with latent tuberculosis or hepatitis B (HBV) need to be excluded when conducting anti-TNF or anti-IL23 therapy in many developing countries.
  • HBV hepatitis B
  • the half-life of systemic antibody therapy is so long that anti-drug antibodies (ADA) are produced to neutralize the antibody drug and reduce its efficacy. Intermittent dosing of anti-TNF antibodies greatly increases the possibility of ADA development, which increases the treatment risk for patients.
  • the object of the present invention is to specifically block the IL-23 heterodimeric receptor molecules by blocking IL-23R, compositions comprising these molecules, methods for screening these molecules, and methods for using these molecules to treat a variety of inflammatory, autoimmune diseases and cancers.
  • These molecules should have good affinity and specificity and be distributed in inflammatory disease tissues so as not to significantly affect systemic immunity.
  • the object of the present invention is to provide a compound represented by general formula (IA), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein the compound represented by general formula (IA) has the following structure:
  • RA is selected from -( CH2 ) mA - RAA ;
  • R AA is selected from -NH 2 , -N + H 3 , -N + (CH 3 ) 3 or -NH-C(O)-CH 3 ;
  • nA is an integer selected from 1 to 6;
  • RA is selected from
  • RB is selected from -( CH2 ) mB - RBB ;
  • RBB is selected from -NR1R2 , -N+ ( R1 ) 2R2 or -NH -C(O) -R1 ;
  • R1 is selected from H, alkyl, or amino acids, preferably, R 1 is selected from H, alkyl;
  • R2 is selected from H, alkyl, or amino acids
  • Ra is selected from H, alkyl, or amino acids
  • R aa is selected from alkyl, or amino acids
  • X1 is selected from amino acids
  • X'1 is selected from amino acids
  • R BB is selected from -NH 2 , -N + H 3 , -N + (CH 3 ) 3 or -NH-C(O)-CH 3 ;
  • n B is an integer selected from 1 to 6;
  • RB is selected from
  • R 3 is selected from hydroxy, alkyl, -NR 6 R 7 or amino acid
  • R 6 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 7 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, alkyl, or amino acids
  • Rcc is selected from alkyl, or amino acids
  • X 5 is selected from amino acids
  • X'5 is selected from amino acids
  • X 6 is selected from amino acids
  • X'6 is selected from amino acids
  • X7 is selected from amino acids
  • X'7 is selected from amino acids
  • R 4 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 5 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids; preferably, selected from
  • R b is selected from H, alkyl, or amino acids, wherein the alkyl group may be further substituted with a hydroxyl group or an alkoxy group;
  • R bb is selected from alkyl, or amino acids
  • X2 is selected from amino acids
  • X'2 is selected from amino acids
  • X 3 is selected from amino acids
  • X'3 is selected from amino acids
  • X 4 is selected from amino acids
  • X'4 is selected from amino acids
  • n1-n2 are each independently selected from integers of 0-12;
  • t2-t9 are each independently selected from integers of 0-12;
  • n4 to m22 are each independently selected from an integer of 0-24.
  • the object of the present invention is to provide a compound represented by general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein the compound represented by general formula (I) has the following structure:
  • R1 and R2 are each independently selected from H, alkyl, or amino acids
  • Ra is selected from H, alkyl, or amino acids
  • R aa is selected from alkyl, or amino acids
  • X1 is selected from amino acids
  • Raa is selected from alkyl, or amino acids
  • X1 is selected from amino acids
  • X'1 is selected from amino acids
  • R 3 is selected from hydroxy, alkyl, -NR 6 R 7 or amino acid
  • R 6 and R 7 are each independently selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, alkyl, or amino acids
  • Rcc is selected from alkyl, or amino acids
  • X 5 is selected from amino acids
  • X 6 is selected from amino acids
  • X7 is selected from amino acids
  • R 3 is selected from hydroxy, alkyl, -NR 6 R 7 or amino acid
  • R 6 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 7 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, alkyl, or amino acids
  • Rcc is selected from alkyl, or amino acids
  • X 5 is selected from amino acids
  • X'5 is selected from amino acids
  • X 6 is selected from amino acids
  • X'6 is selected from amino acids
  • X7 is selected from amino acids
  • X'7 is selected from amino acids
  • R4 and R5 are each independently selected from H, alkyl, -CH2C (O) NH2 , or amino acids;
  • R b is selected from H, alkyl, or amino acids
  • R bb is selected from alkyl, or amino acids
  • X2 is selected from amino acids
  • X 3 is selected from amino acids
  • X 4 is selected from amino acids
  • R 4 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 5 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids; preferably, selected from
  • R b is selected from H, alkyl, or amino acids, wherein the alkyl group may be further substituted with a hydroxyl group or an alkoxy group;
  • R bb is selected from alkyl, or amino acids
  • X2 is selected from amino acids
  • X'2 is selected from amino acids
  • X 3 is selected from amino acids
  • X'3 is selected from amino acids
  • X 4 is selected from amino acids
  • X'4 is selected from amino acids
  • n ⁇ n2 are each independently selected from integers of 0-12;
  • t ⁇ t9 are each independently selected from an integer of 0-12;
  • n ⁇ m21 are each independently selected from an integer of 0-24;
  • n22 is an integer selected from 0 to 24;
  • the compound is not
  • Another object of the present invention is to provide a compound represented by general formula (IV), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein the compound represented by general formula (IV) has the following structure:
  • X1 is selected from amino acids
  • X2 is selected from amino acids
  • R1 and R2 are each independently selected from H, alkyl, or amino acids
  • Ra is selected from H, alkyl, or amino acids
  • R aa is selected from alkyl, or amino acids
  • X1 is selected from amino acids
  • X'1 is selected from amino acids
  • R 3 is selected from hydroxy, alkyl, -NR 6 R 7 or amino acid
  • R 6 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 7 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, alkyl, or amino acids
  • Rcc is selected from alkyl, or amino acids
  • X 5 is selected from amino acids
  • X'5 is selected from amino acids
  • X 6 is selected from amino acids
  • X'6 is selected from amino acids
  • X7 is selected from amino acids
  • X'7 is selected from amino acids
  • R 4 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 5 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R b is selected from H, alkyl, or amino acids, wherein the alkyl group may be further substituted with a hydroxyl group or an alkoxy group;
  • R bb is selected from alkyl, or amino acids
  • X2 is selected from amino acids
  • X'2 is selected from amino acids
  • X 3 is selected from amino acids
  • X'3 is selected from amino acids
  • X 4 is selected from amino acids
  • X'4 is selected from amino acids
  • n ⁇ n2 are each independently selected from integers of 0-12;
  • t ⁇ t9 are each independently selected from an integer of 0-12;
  • n ⁇ m21 are each independently selected from an integer of 0-24;
  • n22 is an integer selected from 0 to 24;
  • the compound is not
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that R1 and R2 are each independently selected from H, alkyl, or amino acids;
  • Ra is selected from H, alkyl, or amino acids
  • R aa is selected from alkyl, or amino acids
  • X1 is selected from amino acids
  • Raa is selected from alkyl, or amino acids
  • X1 is selected from amino acids
  • X'1 is selected from amino acids
  • R3 is selected from hydroxyl
  • R 4 and R 5 are each independently selected from H, alkyl, -CH 2 C(O)NH 2 ;
  • n is an integer selected from 0 to 12;
  • t ⁇ t1 are each independently selected from an integer of 0-12;
  • n to m3 are each independently selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that R 1 and R 2 are selected from H;
  • R 3 is selected from hydroxy, alkyl, -NR 6 R 7 or amino acid
  • R 6 and R 7 are each independently selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, alkyl, or amino acids
  • Rcc is selected from alkyl, or amino acids
  • X 5 is selected from amino acids
  • X 6 is selected from amino acids
  • X7 is selected from amino acids
  • R 3 is selected from hydroxy, alkyl, -NR 6 R 7 or amino acid
  • R 6 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 7 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, alkyl, or amino acids
  • Rcc is selected from alkyl, or amino acids
  • X 5 is selected from amino acids
  • X'5 is selected from amino acids
  • X 6 is selected from amino acids
  • X'6 is selected from amino acids
  • X7 is selected from amino acids
  • X'7 is selected from amino acids
  • R 4 and R 5 are each independently selected from H, alkyl, -CH 2 C(O)NH 2 ;
  • n2 is an integer selected from 0 to 12;
  • t6-t9 are each independently selected from integers of 0-12;
  • n13 to m21 are each independently selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that R 1 and R 2 are selected from H;
  • R3 is selected from hydroxyl
  • R4 and R5 are each independently selected from H, alkyl, -CH2C (O) NH2 , or amino acids;
  • R b is selected from H, alkyl, or amino acids
  • R bb is selected from alkyl, or amino acids
  • X2 is selected from amino acids
  • X 3 is selected from amino acids
  • X 4 is selected from amino acids
  • R 4 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 5 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids; preferably, selected from
  • R b is selected from H, alkyl, or amino acids, wherein the alkyl group may be further substituted with a hydroxyl group or an alkoxy group;
  • R bb is selected from alkyl, or amino acids
  • X2 is selected from amino acids
  • X'2 is selected from amino acids
  • X 3 is selected from amino acids
  • X'3 is selected from amino acids
  • X 4 is selected from amino acids
  • X'4 is selected from amino acids
  • n1 is an integer selected from 0 to 12;
  • t2-t5 are each independently selected from integers of 0-12;
  • n4-m12 are each independently selected from an integer of 0-24;
  • n22 is selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that the compound is further represented by general formula (II):
  • R1 and R2 are each independently selected from H, alkyl, or amino acids
  • Ra is selected from H, alkyl, or amino acids
  • R aa is selected from alkyl, or amino acids
  • X1 is selected from amino acids
  • Raa is selected from alkyl, or amino acids
  • X1 is selected from amino acids
  • X'1 is selected from amino acids
  • R4 is selected from H or alkyl
  • n is an integer selected from 0 to 12;
  • t ⁇ t1 are each independently selected from integers of 0-12;
  • n to m3 are each independently selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that the compound is further represented by general formula (III):
  • R 3 is selected from hydroxy, alkyl, -NR 6 R 7 or amino acid
  • R 6 and R 7 are each independently selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, alkyl, or amino acids
  • Rcc is selected from alkyl, or amino acids
  • X 5 is selected from amino acids
  • X 6 is selected from amino acids
  • X7 is selected from amino acids
  • R 3 is selected from hydroxy, alkyl, -NR 6 R 7 or amino acid
  • R 6 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 7 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, alkyl, or amino acids
  • Rcc is selected from alkyl, or amino acids
  • X 5 is selected from amino acids
  • X'5 is selected from amino acids
  • X 6 is selected from amino acids
  • X'6 is selected from amino acids
  • X7 is selected from amino acids
  • X'7 is selected from amino acids
  • R4 is selected from H or alkyl
  • n2 is an integer selected from 0 to 12;
  • t6-t9 are each independently selected from integers of 0-12;
  • n13 to m21 are each independently selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that the compound further has a compound structure as shown in general formula (V) as follows:
  • X1 is selected from amino acids
  • X2 is selected from amino acids
  • R 4 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 5 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R b is selected from H, alkyl, or amino acids, wherein the alkyl group may be further substituted with a hydroxyl group or an alkoxy group;
  • R bb is selected from alkyl, or amino acids
  • X'2 is selected from amino acids
  • X'3 is selected from amino acids
  • X 4 is selected from amino acids
  • n1 is an integer selected from 0 to 12;
  • t2-t5 are each independently selected from integers of 0-12;
  • n4-m12 are each independently selected from an integer of 0-24;
  • n22 is an integer selected from 0 to 12;
  • the compound is not
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that X1 is selected from Thr, Preferably
  • the compound, its stereoisomer or its pharmaceutically acceptable salt is characterized in that X2 is selected from Preferably
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that the compound is further represented by the general formula (IV):
  • R4 is selected from H or alkyl
  • R 5 is selected from alkyl, -CH 2 C(O)NH 2 , or amino acids
  • R b is selected from H, alkyl, or amino acids
  • R bb is selected from alkyl, or amino acids
  • X2 is selected from amino acids
  • X 3 is selected from amino acids
  • X 4 is selected from amino acids
  • R 4 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 5 is selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids; preferably, selected from
  • R b is selected from H, alkyl, or amino acids, wherein the alkyl group may be further substituted with a hydroxyl group or an alkoxy group;
  • R bb is selected from alkyl, or amino acids
  • X2 is selected from amino acids
  • X'2 is selected from amino acids
  • X 3 is selected from amino acids
  • X'3 is selected from amino acids
  • X 4 is selected from amino acids
  • X'4 is selected from amino acids
  • n1 is an integer selected from 0 to 12;
  • t2-t5 are each independently selected from integers of 0-12;
  • n4-m12 are each independently selected from an integer of 0-24;
  • n22 is selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that R 1 is selected from H, C 1-6 alkyl, or amino acids;
  • R a is selected from H, C 1-6 alkyl, or amino acids
  • R aa is selected from C 1-6 alkyl, or amino acids
  • X1 is selected from amino acids
  • Raa is selected from C1-6 alkyl, or amino acids
  • X1 is selected from amino acids
  • X'1 is selected from amino acids
  • n is an integer selected from 0 to 12;
  • t ⁇ t1 are each independently selected from integers of 0-12;
  • n to m3 are each independently selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that R 2 is selected from H, C 1-6 alkyl, or amino acids;
  • R a is selected from H, C 1-6 alkyl, or amino acids
  • R aa is selected from C 1-6 alkyl, or amino acids
  • X1 is selected from amino acids
  • Raa is selected from C1-6 alkyl, or amino acids
  • X1 is selected from amino acids
  • X'1 is selected from amino acids
  • n is an integer selected from 0 to 12;
  • t ⁇ t1 are each independently selected from integers of 0-12;
  • n to m3 are each independently selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that R 3 is selected from hydroxyl, C 1-6 alkyl, -NR 6 R 7 or amino acid;
  • R 6 and R 7 are each independently selected from H, alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, alkyl, or amino acids
  • Rcc is selected from alkyl, or amino acids
  • X 5 is selected from amino acids
  • X 6 is selected from amino acids
  • X7 is selected from amino acids
  • R 3 is selected from hydroxy, C 1-6 alkyl, -NR 6 R 7 or amino acid;
  • R 6 is selected from H, C 1-6 alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R 7 is selected from H, C 1-6 alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R c is selected from H, C 1-6 alkyl, or amino acids
  • Rcc is selected from C1-6 alkyl, or amino acids
  • X 5 is selected from amino acids
  • X'5 is selected from amino acids
  • X 6 is selected from amino acids
  • X'6 is selected from amino acids
  • X7 is selected from amino acids
  • X'7 is selected from amino acids
  • n2 is an integer selected from 0 to 12;
  • t6-t9 are each independently selected from integers of 0-12;
  • n13 to m21 are each independently selected from an integer of 0-24.
  • the compound, its stereoisomer or pharmaceutically acceptable salt thereof is characterized in that R 4 is selected from H, C 1-6 alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R b is selected from H, C 1-6 alkyl, or amino acids
  • R bb is selected from C 1-6 alkyl, or amino acids
  • X2 is selected from amino acids
  • X 3 is selected from amino acids
  • X 4 is selected from amino acids
  • R 4 is selected from H, C 1-6 alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R b is selected from H, C 1-6 alkyl, or amino acids, wherein the alkyl group may be further substituted with a hydroxyl group or an alkoxy group;
  • R bb is selected from C 1-6 alkyl, or amino acids
  • X2 is selected from amino acids
  • X'2 is selected from amino acids
  • X 3 is selected from amino acids
  • X'3 is selected from amino acids
  • X 4 is selected from amino acids
  • X'4 is selected from amino acids
  • n1 is an integer selected from 0 to 12;
  • t2-t5 are each independently selected from integers of 0-12;
  • n4-m12 are each independently selected from an integer of 0-24;
  • n22 is selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that R 5 is selected from H, C 1-6 alkyl, -CH 2 C(O)NH 2 , or amino acids;
  • R b is selected from H, C 1-6 alkyl, or amino acids
  • R bb is selected from C 1-6 alkyl, or amino acids
  • X2 is selected from amino acids
  • X 3 is selected from amino acids
  • X 4 is selected from amino acids
  • R 5 is selected from H, C 1-6 alkyl, -CH 2 C(O)NH 2 , or amino acids, further preferably, selected from
  • R b is selected from H, C 1-6 alkyl, or amino acid, the alkyl group may be further substituted by hydroxyl or alkoxy;
  • R bb is selected from C 1-6 alkyl, or amino acids;
  • X2 is selected from amino acids
  • X'2 is selected from amino acids
  • X 3 is selected from amino acids
  • X'3 is selected from amino acids
  • X 4 is selected from amino acids
  • X'4 is selected from amino acids
  • n1 is an integer selected from 0 to 12;
  • t2-t5 are each independently selected from integers of 0-12;
  • n4-m12 are each independently selected from an integer of 0-24;
  • n22 is selected from an integer of 0-24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that: Selected from
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that: Selected from
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that: Selected from
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that: Selected from
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that: Selected from Select from
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that: Selected from Select from
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that: Selected from
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that: Selected from
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that: Selected from
  • the amino acid is Gly, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Asp, His, Asn, Glu, Lys, Gln, Met, Arg, Ser, Thr, Cys or Pro;
  • the amino acid is Gln;
  • the amino acid is Gln or Glu.
  • n is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • n1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • n2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t3 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t4 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t5 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t6 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t7 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t8 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • t9 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • n is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m3 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m4 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m5 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m6 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m7 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m8 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m9 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m10 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m11 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m12 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m13 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m14 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m15 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m16 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m17 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m18 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m19 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m20 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • m21 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.
  • m22 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof is characterized in that the amino acid is Gly, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Asp, His, Asn, Glu, Lys, Gln, Met, Arg, Ser, Thr, Cys, Pro,
  • amino acids are Glu, Thr,
  • the present invention also provides a method for preparing the above-mentioned compound, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that it is based on solid phase or liquid phase synthesis;
  • the synthesis method comprises:
  • step 2) cutting the resin peptide obtained in step 1) to obtain a polypeptide intermediate
  • step 4) removing the protecting group of the peptide obtained in step 3) and cyclizing it to obtain the final product;
  • the synthesis method comprises:
  • step 2) cutting the resin peptide obtained in step 1) to obtain a polypeptide intermediate
  • step 3 After removing the protecting group from the peptide obtained in step 3), the peptide is oxidized into a ring through a disulfide bond to obtain the final product.
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective dose of the compound, its stereoisomer or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
  • the pharmaceutical composition is selected from tablets, capsules, liquid preparations or injections.
  • the pharmaceutical composition is a rapid-release preparation or a sustained-release preparation.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof may be administered by any convenient method, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, intrathecal or transdermal administration, and the pharmaceutical composition adjusted accordingly.
  • the compound, its stereoisomer or a pharmaceutically acceptable salt thereof can be formulated into liquid or solid preparations, such as syrups, suspensions, emulsions, tablets, capsules, powders, granules, or lozenges.
  • the present invention further relates to the use of the compound, its stereoisomer or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of IL-23R inhibitor drugs.
  • the present invention further relates to the compounds, stereoisomers or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for use in the preparation of pharmaceutical compositions for treating inflammatory, autoimmune diseases and cancers, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, celiac disease (non-tropical sprue), enteropathy associated with seronegative arthropathy, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radiotherapy or chemotherapy, colitis associated with innate immune disorders such as leukocyte adhesion deficiency-1, chronic granulomatous disease, type 1b glycogen storage disease, Hermansky-Prague syndrome, Sheddie-Donghal syndrome and Weed-Oediger syndrome, pouchitis following proctocolectomy and ileoanal
  • the present invention further relates to the compounds, their stereoisomers or pharmaceutically acceptable salts, or pharmaceutical compositions thereof for use in the preparation of therapeutic agents for the treatment of inflammatory, autoimmune diseases and cancers, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, celiac disease (non-tropical sprue), enteropathy associated with seronegative arthropathy, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radiotherapy or chemotherapy, colitis associated with innate immune disorders such as leukocyte adhesion deficiency-1, chronic granulomatous disease, type 1b glycogen storage disease, Hermansky's disease, and inflammatory bowel disease.
  • IBD inflammatory bowel disease
  • ulcerative colitis Crohn's disease
  • celiac disease non-tropical sprue
  • enteropathy associated with seronegative arthropathy microscopic colitis
  • collagenous colitis eosinophilic gastroenteritis
  • - Prak's syndrome Sheddie-Donghal syndrome and Weed-Oller syndrome
  • pouchitis following proctocolectomy and ileoanal anastomosis gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, irritable bowel syndrome (IBS), multiple sclerosis (MS), psoriasis, psoriatic arthritis, rheumatoid arthritis, pemphigus vulgaris, organ transplant rejection, Crohn's disease, systemic lupus erythematosus (SLE), or diabetic disease.
  • IBS irritable bowel syndrome
  • MS multiple sclerosis
  • psoriasis psoriatic arthritis
  • rheumatoid arthritis pemphigus vulgaris
  • the present invention further relates to a therapeutic prophylactic and/or therapeutic preparative treatment of inflammatory, autoimmune diseases and cancers, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, celiac disease (non-tropical sprue), enteropathy associated with seronegative arthropathy, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radiation therapy or chemotherapy, colitis associated with innate immune disorders such as leukocyte adhesion retardation-1, chronic granulomatous disease, type 1b glycogen storage disease, Hermansky-Prague syndrome, Sheddie-Donghal syndrome and Weed-Oeden syndrome, in the colorectal
  • the present invention also relates to the treatment of inflammatory, autoimmune diseases and cancer in mammals, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, celiac disease (non-tropical sprue), enteropathy associated with seronegative arthropathy, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radiation therapy or chemotherapy, colitis associated with innate immune disorders such as leukocyte adhesion deficiency-1, chronic granulomatous disease, type 1b glycogen storage disease, Hermansky-Prague syndrome, Sheddie-Donghal syndrome and Weed-Oediger syndrome, in proctocolectomy and ileoanal anastomosis
  • a method for treating a condition such as pouchitis caused by postoperative colitis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis
  • the present methods relate to inflammatory, autoimmune diseases and cancers, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, celiac disease (non-tropical sprue), enteropathy associated with seronegative arthropathy, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radiation therapy or chemotherapy, colitis associated with leukocyte adhesion deficiency-1 colitis associated with an innate immune disorder, chronic granulomatous disease, type 1b glycogen storage disease, Hermansky-Prak syndrome, Sheddie-Donghal syndrome, and Weed-Oller syndrome, pouchitis following proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, ps
  • IBD
  • Inflammatory bowel disease arthritis or psoriasis are preferred.
  • peptide refers broadly to a sequence of two or more amino acids joined together by peptide bonds. It should be understood that this term does not imply a specific length of an amino acid polymer, nor is it intended to suggest or distinguish between polypeptides produced using recombinant technology, chemical or enzymatic synthesis, or naturally occurring polypeptides.
  • peptide includes cyclic peptides.
  • amino acid refers to any and all amino acids and residues thereof, including naturally occurring amino acids (e.g., a-amino acids), unnatural amino acids, modified amino acids, synthetic amino acids, or rare amino acids, including both D-amino acids and L-amino acids.
  • Natural amino acids include amino acids found in nature, such as the 23 amino acids that combine into peptide chains to form the building blocks of a large number of proteins. These stereoisomers are primarily L stereoisomers, but some D-amino acids are present in bacterial envelopes and some antibiotics.
  • the 20 "standard" natural amino acids are alanine (Ala); arginine (Arg); asparagine (Asn); aspartic acid (Asp); cysteine (Cys); glutamine (Gln); glutamic acid (Glu); glycine (Gly); histidine (His); isoleucine (Ile); leucine (Leu); lysine (Lys); methionine (Met); phenylalanine (Phe); proline (Pro); serine (Ser); threonine (Thr); tryptophan (Trp); tyrosine (Tyr); and valine (Val).
  • non-standard natural amino acids are pyrrolysine (found in methanogens and other eukaryotic organisms), selenocysteine (present in many non-eukaryotic organisms as well as most eukaryotic organisms), and N-formylmethionine (encoded by the start codon AUG in bacteria, mitochondria, and chloroplasts).
  • Non-natural or “unnatural amino acids” are naturally occurring or chemically synthesized non-proteinogenic amino acids (i.e., amino acids that are not naturally encoded or found in the genetic code). More than 140 non-natural amino acids are known and there are potentially thousands of combinations.
  • non-natural amino acids include ⁇ -amino acids ( ⁇ 3 and ⁇ 2 ), homoamino acids, proline derivatives and pyruvate derivatives, 3 substituted alanine derivatives, glycine derivatives, ring-substituted phenylalanine and tyrosine derivatives, linear nuclear amino acids, diamino acids, D-diamino acids, ⁇ -methyl amino acids and N-methyl amino acids.
  • Non-natural or unnatural amino acids also include modified amino acids.
  • Modified amino acids include amino acids (e.g., natural amino acids) that have been chemically modified to include a group or chemical moiety that is not naturally present on the amino acid.
  • the non-natural amino acids described herein include, but are not limited to,
  • alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl,
  • lower alkyl groups containing 1 to 6 carbon atoms are preferred, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like.
  • the hydrogen atoms described in the present invention can be replaced by their isotope deuterium, and any hydrogen atom in the example compounds of the present invention can also be replaced by a deuterium atom.
  • Hydrophilicity refers to an -OH group.
  • THF tetrahydrofuran
  • MeOH refers to methanol
  • DMF N,N-dimethylformamide
  • TFA trifluoroacetic acid
  • TAA triethylamine
  • MeI refers to methyl iodide
  • DMA refers to N,N-dimethylacetamide.
  • Et2O refers to diethyl ether.
  • DCM dichloromethane
  • DMAP refers to 4-dimethylaminopyridine.
  • DCC refers to dicyclohexylcarbodiimide.
  • DCE refers to 1,2-dichloroethane.
  • DIEA refers to N,N-diisopropylethylamine.
  • NBS N-bromosuccinimide
  • NIS N-iodosuccinimide
  • Cbz-Cl refers to benzyl chloroformate
  • Pd 2 (dba) 3 refers to tris(dibenzylideneacetone)dipalladium.
  • Dppf refers to 1,1'-bis(diphenylphosphino)ferrocene.
  • HATU refers to 2-(7-oxybenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate.
  • KHMDS refers to potassium hexamethyldisilazide
  • LiHMDS refers to lithium bistrimethylsilylamide.
  • MeLi refers to methyllithium
  • n-BuLi refers to n-butyllithium
  • NaBH(OAc) 3 refers to sodium triacetoxyborohydride.
  • “Pharmaceutical composition” means a mixture containing one or more compounds described herein or their physiologically/pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically/pharmaceutically acceptable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
  • “Pharmaceutically acceptable salts” refer to salts of the compounds of the present invention, which are safe and effective when used in mammals and have the desired biological activity.
  • the structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or/and liquid chromatography-mass spectrometry (LC-MS).
  • NMR chemical shift ( ⁇ ) is given in parts per million (ppm).
  • the NMR measurement is performed using a Bruker AVANCE-400 nuclear magnetic spectrometer, the measurement solvent is deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated methanol (CD 3 OD), deuterated chloroform (CDCl 3 ) or deuterated water (D 2 O), and the internal standard is tetramethylsilane (TMS).
  • DMSO-d 6 deuterated dimethyl sulfoxide
  • CD 3 OD deuterated methanol
  • CDCl 3 deuterated chloroform
  • D 2 O deuterated water
  • TMS tetramethylsilane
  • LC-MS The determination of LC-MS was performed by electrospray ion chromatography: Thermo Scientific-LTQ-XL, and the determination of HPLC was performed by Agilent 1260 high pressure liquid chromatograph (Phenomenex Gemini C18, 4.6 ⁇ 150mm, 5 ⁇ m column).
  • the thin layer chromatography silica gel plate used Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate.
  • the specifications used for TLC were 0.15mm ⁇ 0.20mm, and the specifications used for thin layer chromatography separation and purification products were 0.4mm ⁇ 0.5mm.
  • Column chromatography generally uses Yantai Huanghai silica gel 200 ⁇ 300 mesh silica gel as the carrier.
  • the starting materials in the examples of the present invention are known and can be purchased on the market, or can be synthesized by or according to methods known in the art.
  • the eluent system of silica gel column chromatography and the developing solvent system of thin layer chromatography used for the intermediates and purified compounds in the examples include: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: dichloromethane and acetone system.
  • C dichloromethane and acetone system.
  • the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.
  • L-phenylglycine (3.35 g, 40.26 mmol) was dissolved in methanol (150 mL), cooled to -78 °C, and a methanol solution (20 mL) of 6,6-dimethylbicyclo[3.1.0]hexan-3-one A1a (CAS: 13855-29-3, 5.0 g, 40.26 mmol) and a methanol solution (20 mL) of tert-butyl isocyanate were added dropwise in sequence, and the temperature was gradually raised to room temperature for reaction for 24 hours. The reaction solution was concentrated and dissolved in 200 mL of ether for slurrying, and the insoluble matter was filtered off.
  • reaction solution was filtered through diatomaceous earth, the filtrate was concentrated and dissolved in ether (150 mL), extracted twice with 2N dilute hydrochloric acid (50 mL), the aqueous phases were combined, the pH was adjusted to 8 with potassium carbonate solid, extracted twice with ether (100 mL), and concentrated under reduced pressure to obtain 3-amino-N-(tert-butyl)-6,6-dimethylbicyclo[3.1.0]hexane-3-carboxamide A1c (4.9 g), with a yield of 81.4%.
  • aqueous phase was adjusted to pH 2 with 2N dilute hydrochloric acid and extracted twice with ethyl acetate (50 mL).
  • the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was purified by centrifugation. After concentration, the residue was purified by silica gel column chromatography (MeOH/DCM system gradient elution) to give intermediate A1 3-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-6,6-dimethylbicyclo[3.1.0]hexane-3-carboxylic acid (5.6 g) in a yield of 66.9%.
  • intermediate A2 1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(difluoromethylene)cyclohexane-1-carboxylic acid was obtained through 4-(difluoromethylene)cyclohexanone (CAS:137780-61-1) and subsequent similar experimental operations.
  • A3b (61.5 g, 433.0 mmol) was dissolved in a mixed solution of dioxane (300 mL) and water (300 mL), and sodium carbonate (55.1 g, 519.7 mmol) was added.
  • reaction solution was slurried with water (400 mL), filtered to obtain a white solid, and the obtained solid was slurried with petroleum ether (300 mL), filtered and dried to obtain (9H-fluoren-9-yl)methyl (4-cyanotetrahydro-2H-thiopyran-4-yl)carbamate A3c (124 g), with a yield of 79%.
  • A3d (38.1 g, 96.2 mmol) was dissolved in 4N hydrochloric acid dioxane solution (300 mL), and then concentrated hydrochloric acid (400 mL) was added and stirred at 90°C for 30 h.
  • the reaction solution was concentrated to 200 mL, and water (400 mL) was added to slurry to precipitate solids.
  • the solids were filtered and slurried with ethyl acetate (200 mL). The solids were filtered and dried to obtain intermediate A3 (12.77 g, purity: 97.80%).
  • Step 1 Synthesis of fully protected linear peptides
  • Step 2 Cleavage of fully protected linear peptide
  • Step 3 Condensation of intermediate 1c with intermediate A
  • Step 4 Cleavage of linear peptides
  • Example 2 Referring to the synthesis method of Example 1, 26.4 mg of product Example 2 was obtained through the reaction of intermediate B with polypeptide intermediate 1c and subsequent similar experimental operations, with a purity of 92.94% and a yield of 13.6%.
  • Example 3 Referring to the synthesis method of Example 1, 42.0 mg of the product Example 3 was obtained through the reaction of the intermediate L1 and the polypeptide intermediate 1c and subsequent similar experimental operations, with a purity of 96.4% and a yield of 20.2%.
  • Example 4 Referring to the synthesis method of Example 1, 28.1 mg of product Example 4 was obtained through the reaction of intermediate L3 with polypeptide intermediate 1c and subsequent similar experimental operations, with a purity of 96.2% and a yield of 14.9%.
  • Example 6 Referring to the synthesis method of Example 1, 31.2 mg of product Example 6 was obtained through the reaction of intermediate L5 with polypeptide intermediate 1c and subsequent similar experimental operations, with a purity of 97.8% and a yield of 18.1%.
  • Example 12 Referring to the synthesis method of Example 1, 23.8 mg of product Example 12 was obtained through the reaction of intermediate L2 and polypeptide intermediate 1c and subsequent similar experimental operations, with a purity of 95.7% and a yield of 17.5%.
  • Example 12 can also be prepared by the following method:
  • Step 1 Condensation of intermediate 1c with intermediate L2
  • the intermediate 12d obtained in the previous step was added to the prepared cutting solution, shaken on a shaker for 2.5 hours, filtered, and the filtrate was added to the 10-fold
  • the product was accumulated in icy isopropyl ether, centrifuged, washed three times with isopropyl ether, and dried in vacuo for 2 hours to obtain intermediate 12e.
  • Step 3 Oxidation and purification of disulfide bonds and salt transfer
  • the intermediate 12e (190 mg) obtained above was added with water (160 mL) and acetonitrile (40 mL), and after dissolution and clarification, 0.1 M I 2 /MeOH was slowly added dropwise until the solution turned bright yellow. The yellow color did not disappear after stirring for 5 minutes, and then 0.1 M sodium thiosulfate was added dropwise until the yellow color disappeared. After stirring for 2 minutes without change, the reaction solution of Example 12 was obtained.
  • the reaction solution was purified under the following purification conditions.
  • Example 20 35.1 mg of product Example 20 was obtained through the reaction of intermediate L4 with polypeptide intermediate 1c and subsequent similar experimental operations, with a purity of 97.1% and a yield of 19.1%.
  • Step 1 Solid-phase synthesis of fully protected linear peptides
  • the resin After sampling and testing with ninhydrin, the resin turns blue.
  • Step 2 Cleavage and deprotection of linear peptides
  • the obtained resin peptide 1-14b was added with 10 mL of the prepared cutting solution, shaken in a water bath shaker at 25°C for 2.5 hours, filtered, and the filtrate was added to 10 times the volume of ice isopropyl ether, centrifuged, and the supernatant was discarded.
  • the crude peptide 1-14c was then washed with isopropyl ether for 3 times and vacuum dried for 2 hours to obtain the crude peptide 1-14c.
  • the crude peptide 1-14c (190 mg) obtained above was added to water (100 mL) and acetonitrile (100 mL), and after dissolution and clarification, 0.1 M I 2 /MeOH was slowly added dropwise until the solution turned bright yellow. The yellow color did not disappear after stirring for 5 minutes, and then 0.1 M sodium thiosulfate was added dropwise until the yellow color disappeared. After stirring for two minutes without change, the sample was purified under the following purification conditions.
  • the purified solution was concentrated under reduced pressure to remove the organic solvent and lyophilized to obtain 45 mg of the final product Example 1-14, with a purity of 97.5% and a yield of 11.7%.
  • Step 1 Synthesis of fully protected linear peptides
  • reaction liquid was removed and washed with DMF 5 times (20 mL each time), 1 minute each time, and then discharged until no liquid flowed out to obtain the linear peptide 1-16-1b.
  • Step 2 Cleavage of fully protected linear peptide
  • Step 3 Condensation of intermediate 1-16-1c with intermediate A
  • Step 4 Cleavage of linear peptides
  • the crude peptide obtained in the third step was added to the prepared cutting solution, shaken on a shaker for 2.5 hours, filtered, and the filtrate was added to 10 volumes of ice isopropyl ether, centrifuged, and washed with isopropyl ether for 3 times.
  • the crude peptide 1-16-1e was obtained by vacuum drying for 2 hours.
  • Example 3-16-1 can be prepared by referring to the following method:
  • Example 1-16-1 Refer to the preparation method of Example 1-16-1, wherein 1-(9H-fluorene-9-ylmethoxycarbonylamino)-4,4-difluoro-cyclohexanecarboxylic acid in the first step of the linear peptide solid phase synthesis is replaced with (9H-fluorene-9-yl)methyl(4-cyanotetrahydro-2H-thiopyran-4-yl)carbamate A3c to obtain 120 mg of the product Example 3-16-1 with a purity of 98.5% and a yield of 23.0%.
  • Example 4-16-1 can be prepared by referring to the following method:
  • Example 1-16-1 Refer to the preparation method of Example 1-16-1, wherein 1-(9H-fluoren-9-ylmethoxycarbonylamino)-4,4-difluoro-cyclohexanecarboxylic acid in the first step of the linear peptide solid phase synthesis is replaced with intermediate A3 to obtain 110 mg of product Example 4-16-1 with a purity of 99.4% and a yield of 21.0%.
  • Examples 1-19 can be prepared by referring to the following method:
  • intermediate A in the third step of coupling the linear peptide with the side chain was replaced with intermediate L2 to obtain 110 mg of product Example 1-19 with a purity of 95.1% and a yield of 15.4%.
  • Examples 3-19 can be prepared by referring to the following method:
  • Example 1-16-1 Refer to the preparation method of Example 1-16-1, wherein 1-(9H-fluorene-9-ylmethoxycarbonylamino)-4,4-difluoro-cyclohexanecarboxylic acid in the first step of the linear peptide solid phase synthesis is replaced by (9H-fluorene-9-yl)methyl(4-cyanotetrahydro-2H-thiopyran-4-yl)carbamate A3c, and the side chain intermediate A in the third step of the linear peptide and side chain coupling is replaced by intermediate L2 to obtain 110 mg of product Example 3-19 with a purity of 99.0% and a yield of 15.4%.
  • Examples 4-19 can be prepared by referring to the following method:
  • Example 1-16-1 1-(9H-fluorene-9-ylmethoxycarbonylamino)-4,4-difluoro-cyclohexanecarboxylic acid in the first step of the linear peptide solid phase synthesis is replaced by intermediate A3, and the side chain intermediate A in the third step of the linear peptide and side chain coupling is replaced by intermediate L2 to obtain 102 mg of product Example 4-19 with a purity of 99.8% and a yield of 14.2%.
  • R1 and R2 are selected from the following structures
  • Test Example 1 Experiment on the competition between the compound of the present invention and IL23 for binding to IL23R
  • the compounds of the present invention were screened in IL23/IL23R BINDING ASSAY KITS (PerkinElmer Cat#64BDPIL23PEH).
  • the screening of the compounds of the present invention was carried out in the form of a multi-well plate (suitable for HTRF determination).
  • 2 ⁇ l of several compounds of the present invention and STANDARD SOLUTIONS in the KIT were added to the wells of the multi-well plate, and 4 ⁇ l Tag1-IL23, 4 ⁇ l Tag2-IL23R and 10 ⁇ L of pre-mixed Anti-Tag1 Eu Cryptate Antibody and Anti-Tag2d2reagent were added to all wells.
  • the multi-well plate was protected from light using an opaque film, and the opaque film was removed after incubation at room temperature for 2 hours, and the signal value was read using an HTRF-compatible detection instrument to detect the IC 50 value.
  • the inhibition rate was calculated as follows:
  • %inhibition (Signal cmpd-Signal Ave_PC)/(Signal Ave_VC-Signal Ave_PC) ⁇ 100.
  • H Ave(DMSO);
  • L Ave(Guselkumab)
  • the HTRF experimental results data were fitted with nonlinear regression using log(inhibitor) vs.response--Variable slope(four parameters) in Graphpad, and the curve was fitted to obtain the IC 50 value.
  • Test Example 2 Experiment on the competition between the compounds of the present invention and IL12 for binding to IL12R ⁇ 1
  • the compounds of the present invention were screened in IL12/IL12RB1 BINDING ASSAY KITS (PerkinElmer Cat#64BDIL12PEG).
  • the screening of the compounds of the present invention was carried out in the form of a multi-well plate (suitable for HTRF determination).
  • 2 ⁇ l of several compounds of the present invention and STANDARD SOLUTIONS in the KIT were added to the wells of the multi-well plate, and 4 ⁇ l Tag1-IL12, 4 ⁇ l Tag2-IL12Rb1 and 10 ⁇ L of pre-mixed Anti-Tag1 Eu Cryptate Antibody and Anti-Tag2XL665reagent were added to all wells.
  • the multi-well plate was protected from light using an opaque film, and the opaque film was removed after incubation at room temperature for 2 hours, and the signal value was read using an HTRF-compatible detection instrument to detect the IC 50 value.
  • the inhibition rate was calculated as follows:
  • %inhibition (Signal cmpd-Signal Ave_PC)/(Signal Ave_VC-Signal Ave_PC) ⁇ 100.
  • H Ave(DMSO);
  • L Ave(Guselkumab)
  • the HTRF experimental results data were fitted with nonlinear regression using log(inhibitor) vs.response--Variable slope(four parameters) in Graphpad, and the curve was fitted to obtain the IC 50 value.
  • the above scheme indicates that the compound of the present invention exhibits a biological activity greater than 1000 nM (IC 50 ) in an inhibition test of competing with IL12 for binding to IL12R ⁇ 1.
  • Test Example 3 Experiment on the blocking effect of the compounds of the present invention on the phosphorylation of STAT3 in DB cells activated by hIL23
  • the lysate was measured for p-STAT3 content using PathScan Phospho-Stat3 (Tyr705) Sandwich ELISA Kit (CST Cat#7300C), and the activity of the compounds of the present invention in blocking rhIL23 signal transduction on DB cells was calculated.
  • the inhibition rate was calculated as follows:
  • Inhibition% (Ave_H-Sample)/(Ave_H-Ave_L) ⁇ 100
  • the ELISA experimental results data were fitted with nonlinear regression using log (inhibitor) vs. response--Variable slope (four parameters) in Graphpad, and the curve was fitted to obtain the IC 50 value.
  • the compounds implemented by the present invention are self-made.
  • Each group contained 3 male SD rats. Shanghai JXJ Experimental Animal Co., Ltd., animal production license number (SCXK (Shanghai) 2013-0006N0.311620400001794).
  • Oral drug preparation 20% Labrasol
  • the example compound was weighed and dissolved in the solution, shaken and sonicated for 5 minutes to obtain a colorless clear solution with a concentration of 0.5 mg/mL.
  • the example compound was weighed and dissolved in the solution, vortexed and ultrasonicated for 5 minutes, and filtered through a 0.22 ⁇ m filter membrane to obtain a colorless clear solution with a concentration of 0.2 mg/mL.
  • Three male SD rats were administered PO after overnight fasting at a dose of 5 mg/kg in a dosing volume of 10 mL/kg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PCT/CN2023/135637 2022-11-30 2023-11-30 一种多肽抑制剂、其制备方法和应用 Ceased WO2024114762A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020257019116A KR20250111134A (ko) 2022-11-30 2023-11-30 폴리펩티드 억제제, 이의 제조 방법 및 응용
CN202380079192.7A CN120202212A (zh) 2022-11-30 2023-11-30 一种多肽抑制剂、其制备方法和应用
US19/133,875 US20260193294A1 (en) 2022-11-30 2023-11-30 Polypeptide inhibitor, and preparation method therefor and use thereof
JP2025531331A JP2025540765A (ja) 2022-11-30 2023-11-30 ポリペプチド阻害剤、その製造方法及び応用
EP23896904.2A EP4628499A1 (en) 2022-11-30 2023-11-30 Polypeptide inhibitor, and preparation method therefor and use thereof
AU2023404553A AU2023404553A1 (en) 2022-11-30 2023-11-30 Polypeptide inhibitor, and preparation method therefor and use thereof
IL321139A IL321139A (en) 2022-11-30 2023-11-30 Polypeptide inhibitor, method for its preparation and use
MX2025006152A MX2025006152A (es) 2022-11-30 2025-05-27 Inhibidor polipeptidico, metodo de preparacion del mismo y uso del mismo

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CN202211530438.1 2022-11-30
CN202211530438 2022-11-30
CN202310206299.5 2023-03-03
CN202310206299 2023-03-03
CN202310261818.8 2023-03-15
CN202310261818 2023-03-15
CN202310349519.X 2023-03-31
CN202310349519 2023-03-31
CN202311144489.5 2023-09-05
CN202311144489 2023-09-05

Publications (1)

Publication Number Publication Date
WO2024114762A1 true WO2024114762A1 (zh) 2024-06-06

Family

ID=91323029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/135637 Ceased WO2024114762A1 (zh) 2022-11-30 2023-11-30 一种多肽抑制剂、其制备方法和应用

Country Status (10)

Country Link
US (1) US20260193294A1 (cg-RX-API-DMAC7.html)
EP (1) EP4628499A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025540765A (cg-RX-API-DMAC7.html)
KR (1) KR20250111134A (cg-RX-API-DMAC7.html)
CN (1) CN120202212A (cg-RX-API-DMAC7.html)
AU (1) AU2023404553A1 (cg-RX-API-DMAC7.html)
IL (1) IL321139A (cg-RX-API-DMAC7.html)
MX (1) MX2025006152A (cg-RX-API-DMAC7.html)
TW (1) TW202440611A (cg-RX-API-DMAC7.html)
WO (1) WO2024114762A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242221A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 新型修饰侧链、其制备方法和应用
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026052109A1 (zh) * 2024-09-06 2026-03-12 上海翰森生物医药科技有限公司 一种多肽抑制剂的药物组合物及其用途
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206254A (zh) * 2014-07-17 2017-09-26 领导医疗有限公司 白细胞介素‑23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2021041770A1 (en) 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
WO2021127460A1 (en) 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
WO2022109328A1 (en) * 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
CN115279782A (zh) * 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
CN115298196A (zh) * 2020-01-15 2022-11-04 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206254A (zh) * 2014-07-17 2017-09-26 领导医疗有限公司 白细胞介素‑23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CN113563423A (zh) * 2014-07-17 2021-10-29 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2021041770A1 (en) 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
WO2021127460A1 (en) 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
CN115279782A (zh) * 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
CN115298196A (zh) * 2020-01-15 2022-11-04 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
WO2022109328A1 (en) * 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
no. 1986905-26-3
See also references of EP4628499A1

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242221A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 新型修饰侧链、其制备方法和应用
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026052109A1 (zh) * 2024-09-06 2026-03-12 上海翰森生物医药科技有限公司 一种多肽抑制剂的药物组合物及其用途
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Also Published As

Publication number Publication date
IL321139A (en) 2025-07-01
JP2025540765A (ja) 2025-12-16
MX2025006152A (es) 2025-07-01
CN120202212A (zh) 2025-06-24
US20260193294A1 (en) 2026-07-09
AU2023404553A1 (en) 2025-07-10
TW202440611A (zh) 2024-10-16
KR20250111134A (ko) 2025-07-22
EP4628499A1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
CN120202212A (zh) 一种多肽抑制剂、其制备方法和应用
CN111065623B (zh) 用于抗体药物缀合物的接头
Schiller et al. Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analog: effects on receptor selectivity and stereospecificity
JP2022542286A (ja) ヘテロタンデム二環式ペプチド複合体
EP4370532A2 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
JP2514518B2 (ja) ヘプタペプチドおよびオクタペプチドのソマトスタチン類似アミド誘導体、それを含有する抗腫瘍剤
WO2022171101A1 (zh) 一种甾体偶联物
CA3240982A1 (en) Peptide inhibitors of interleukin-23 receptor
WO2023040793A1 (zh) 一种抗炎症的化合物及其用途
WO2024227437A1 (zh) 白介素-23受体的肽抑制剂制备及其用途
WO2021161263A1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof
JPH07508748A (ja) ヒト白血球エラスターゼに対する阻害剤としてのフッ素含有ジペプチド
EP4612144A1 (en) Carbonic anhydrase ix ligands for targeted delivery applications
CA2197566A1 (en) New peptide derivatives with .delta. opioid receptor antagonist or mixed.mu. agonist/.delta. antagonist effects
IE57717B1 (en) Lh/rh antagonists
US11866518B2 (en) Bicyclic peptide ligands specific for TSLP
CA2061993A1 (en) Fucose-bearing cytostatics
US4031070A (en) Tetrapeptides
EP4471049A1 (en) Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) Peptide inhibitors of interleukin-23 receptor
EP4652182A1 (en) Peptide inhibitors of interleukin-23 receptor
WO2026041110A1 (zh) 一种多肽化合物及其应用
JPS6110553A (ja) プロリン誘導体
MXPA98000757A (es) Derivados de amidas de los acidos isoxazolico y crotonico y su utilizacion como medicamentos y agentes de diagnostico

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23896904

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202380079192.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 321139

Country of ref document: IL

Ref document number: MX/A/2025/006152

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2025531331

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2501003545

Country of ref document: TH

Ref document number: 2025531331

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025010950

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202547059922

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 822721

Country of ref document: NZ

Ref document number: AU2023404553

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 202380079192.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 822721

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2023896904

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: MX/A/2025/006152

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 202547059922

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2023896904

Country of ref document: EP

Effective date: 20250630

ENP Entry into the national phase

Ref document number: 2023404553

Country of ref document: AU

Date of ref document: 20231130

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020257019116

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11202503606T

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202503606T

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 2023896904

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112025010950

Country of ref document: BR

Free format text: APRESENTE NOVAS FOLHAS DO (RELATORIO DESCRITIVO) ADAPTADAS AO ART. 20 DA PORTARIA/INPI/NO 14/2024, UMA VEZ QUE O CONTEUDO ENVIADO NA PETICAO NO 870250064526 DE 25/07/2025 ENCONTRA-SE FORA DA NORMA NO QUE SE REFERE A NUMERACAO DAS TABELAS, MAIS ESPECIFICAMENTE AS TABELAS DO RELATORIO DESCRITIVO NAO ESTAO NUMERADAS. A EXIGENCIA DEVE SER RESPONDIDA EM ATE 60 (SESSENTA) DIAS DE SUA PUBLICACAO E DEVE SER REALIZADA POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207.

ENP Entry into the national phase

Ref document number: 112025010950

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250529